vs
Ceribell, Inc.（CBLL）与FONAR CORP（FONR）财务数据对比。点击上方公司名可切换其他公司
FONAR CORP的季度营收约是Ceribell, Inc.的1.0倍（$25.5M vs $24.8M）。FONAR CORP净利率更高（8.0% vs -54.6%，领先62.6%）。FONAR CORP自由现金流更多（$-227.0K vs $-11.0M）
Ceribell, Inc.是一家专注于神经诊断领域的医疗科技企业，主打便携式快速脑电图检测设备，可为急症、重症护理场景提供便捷的癫痫发作监测解决方案，核心市场覆盖北美地区，目前正逐步推进全球化业务布局。
FONAR是一家专业医疗技术企业，专注于设计、制造及销售包括立式、开放式在内的创新磁共振成像（MRI）设备，主要服务美国的医院、影像诊断中心及医疗机构，为临床诊断提供高精度扫描解决方案。
CBLL vs FONR — 直观对比
营收规模更大
FONR
是对方的1.0倍
$24.8M
净利率更高
FONR
高出62.6%
-54.6%
自由现金流更多
FONR
多$10.7M
$-11.0M
损益表 — Q4 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $24.8M | $25.5M |
| 净利润 | $-13.5M | $2.1M |
| 毛利率 | 87.3% | — |
| 营业利润率 | -58.9% | 13.5% |
| 净利率 | -54.6% | 8.0% |
| 营收同比 | — | 2.4% |
| 净利润同比 | — | 4.7% |
| 每股收益（稀释后） | $-0.35 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBLLFONR
| Q4 25 | $24.8M | $25.5M | ||
| Q3 25 | $22.6M | $26.0M | ||
| Q2 25 | $21.2M | $27.3M | ||
| Q1 25 | $20.5M | $27.2M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | $17.2M | $25.0M | ||
| Q2 24 | — | $25.9M | ||
| Q1 24 | — | $25.7M |
净利润CBLLFONR
| Q4 25 | $-13.5M | $2.1M | ||
| Q3 25 | $-13.5M | $2.3M | ||
| Q2 25 | $-13.6M | $729.3K | ||
| Q1 25 | $-12.8M | $2.5M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | $-10.4M | $3.1M | ||
| Q2 24 | — | $830.4K | ||
| Q1 24 | — | $1.9M |
毛利率CBLLFONR
| Q4 25 | 87.3% | — | ||
| Q3 25 | 88.3% | — | ||
| Q2 25 | 88.1% | — | ||
| Q1 25 | 87.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 87.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率CBLLFONR
| Q4 25 | -58.9% | 13.5% | ||
| Q3 25 | -64.8% | 14.1% | ||
| Q2 25 | -70.5% | 5.3% | ||
| Q1 25 | -69.3% | 15.2% | ||
| Q4 24 | — | 11.9% | ||
| Q3 24 | -57.8% | 21.0% | ||
| Q2 24 | — | 7.4% | ||
| Q1 24 | — | 16.8% |
净利率CBLLFONR
| Q4 25 | -54.6% | 8.0% | ||
| Q3 25 | -59.6% | 8.7% | ||
| Q2 25 | -64.4% | 2.7% | ||
| Q1 25 | -62.4% | 9.2% | ||
| Q4 24 | — | 7.9% | ||
| Q3 24 | -60.6% | 12.6% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 7.3% |
每股收益（稀释后）CBLLFONR
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.37 | — | ||
| Q2 25 | $-0.38 | — | ||
| Q1 25 | $-0.36 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.85 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $159.3M | $121.0K |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $155.3M | $176.9M |
| 总资产 | $195.8M | $217.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CBLLFONR
| Q4 25 | $159.3M | $121.0K | ||
| Q3 25 | $168.5M | $122.0K | ||
| Q2 25 | $177.4M | $56.5M | ||
| Q1 25 | $182.7M | $123.0K | ||
| Q4 24 | — | $121.0K | ||
| Q3 24 | $14.1M | $136.0K | ||
| Q2 24 | — | $56.5M | ||
| Q1 24 | — | $134.0K |
总债务CBLLFONR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $66.9K | ||
| Q1 24 | — | — |
股东权益CBLLFONR
| Q4 25 | $155.3M | $176.9M | ||
| Q3 25 | $164.1M | $174.9M | ||
| Q2 25 | $172.2M | $172.6M | ||
| Q1 25 | $180.9M | $171.9M | ||
| Q4 24 | — | $169.8M | ||
| Q3 24 | $-136.0M | $168.7M | ||
| Q2 24 | — | $166.0M | ||
| Q1 24 | — | $165.8M |
总资产CBLLFONR
| Q4 25 | $195.8M | $217.2M | ||
| Q3 25 | $199.5M | $218.4M | ||
| Q2 25 | $207.7M | $216.9M | ||
| Q1 25 | $213.5M | $214.9M | ||
| Q4 24 | — | $208.0M | ||
| Q3 24 | $47.1M | $212.3M | ||
| Q2 24 | — | $214.2M | ||
| Q1 24 | — | $209.6M |
负债/权益比CBLLFONR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-10.8M | $171.0K |
| 自由现金流经营现金流 - 资本支出 | $-11.0M | $-227.0K |
| 自由现金流率自由现金流/营收 | -44.2% | -0.9% |
| 资本支出强度资本支出/营收 | 0.7% | 1.6% |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $-41.6M | $5.7M |
8季度趋势，按日历期对齐
经营现金流CBLLFONR
| Q4 25 | $-10.8M | $171.0K | ||
| Q3 25 | $-11.1M | $1.7M | ||
| Q2 25 | $-7.5M | $4.2M | ||
| Q1 25 | $-11.4M | $3.1M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $4.6M | ||
| Q1 24 | — | $2.8M |
自由现金流CBLLFONR
| Q4 25 | $-11.0M | $-227.0K | ||
| Q3 25 | $-11.5M | $-177.0K | ||
| Q2 25 | $-7.6M | $3.6M | ||
| Q1 25 | $-11.6M | $2.6M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | — | $-148.0K | ||
| Q2 24 | — | $4.2M | ||
| Q1 24 | — | $2.6M |
自由现金流率CBLLFONR
| Q4 25 | -44.2% | -0.9% | ||
| Q3 25 | -50.8% | -0.7% | ||
| Q2 25 | -35.9% | 13.1% | ||
| Q1 25 | -56.4% | 9.4% | ||
| Q4 24 | — | 6.0% | ||
| Q3 24 | — | -0.6% | ||
| Q2 24 | — | 16.1% | ||
| Q1 24 | — | 10.2% |
资本支出强度CBLLFONR
| Q4 25 | 0.7% | 1.6% | ||
| Q3 25 | 1.6% | 7.2% | ||
| Q2 25 | 0.3% | 2.4% | ||
| Q1 25 | 0.7% | 2.2% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | — | 1.6% | ||
| Q1 24 | — | 0.7% |
现金转化率CBLLFONR
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.75× | ||
| Q2 25 | — | 5.79× | ||
| Q1 25 | — | 1.26× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | — | 5.54× | ||
| Q1 24 | — | 1.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBLL
| Products | $18.8M | 76% |
| Subscription | $6.0M | 24% |
FONR
| Managementof Diagnostic Imaging Centers | $23.2M | 91% |
| Manufacturingand Servicingof Medical Equipment | $2.4M | 9% |
